Helsinn and Mundipharma China Pharmaceutical jointly announce NMPA’s approval of the oral formulation of Akynzeo® in China

    NEXT STORY
    Roche ranked as one of the most sustainable healthcare companies in the Dow Jones Sustainability Indices for the eleventh year running
    PREV STORY
    Lundbeck to acquire Alder BioPharmaceuticals – a company committed to transforming migraine treatment and prevention – in a transaction valued at up to USD 1.95 billion net of cash
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

     Sorrento Therapeutics CEO Dr. Ji to Present at Roth Capital Partners 30th Annual Growth Stock Conference on 03/12/18

    SAN DIEGO, March 08, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE) ("Sorrento"), announced ...

    author_avatar
    NASDAQ Market News

    Dynavax Announces First Participants Dosed in Phase 1 Clinical Trial Evaluating Clover Biopharmaceuticals’ COVID-19 S-Trimer Vaccine Candidate with CpG 1018 Adjuvant

    author_avatar
    NASDAQ Market News

    Helsinn Group and MEI Pharma Announce Upcoming Presentation at ASCO 2018 on the design of the Phase III PRIMULA study of Pracinostat in combination with azacitidine for the treatment of Acute Myeloid Leukemia (AML) in adult patients unfit f

    Helsinn Group and MEI Pharma Announce Upcoming Presentation at ASCO 2018 on the design ...

    author_avatar
    NASDAQ Market News